222. Primary nephrotic syndrome Clinical trials / Disease details


Clinical trials : 310 Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04424862
(ClinicalTrials.gov)
June 9, 20207/6/2020Multitarget Therapy for Idiopathic Membranous NephropathyMultitarget Therapy for Idiopathic Membranous NephropathyEfficacyDrug: Prednisone, ciclosporin and mycophenolate mofetil;Drug: Ponticelli RegimenBeijing Friendship HospitalNULLCompleted18 Years70 YearsAll82Phase 4China
2JPRN-UMIN000001099
2007/10/0131/03/2008Optimal use of ciclosporin in idiopathic membranous nephropathy associated with nephrotic syndromeOptimal use of ciclosporin in idiopathic membranous nephropathy associated with nephrotic syndrome - Optimal use of ciclosporin in membranous nephropathy (OCIM-NS study) idiopathic membranous nephropathy associated with nephrotic syndromeSteroid group: Immunosuppressive therapy is started by predonisolone 0.8mg/kg/day (max 60mg/day). The dose is decreased by 5mg/day in 2 to 4 weeks after remission. The cases who do not reach remission for 4 weeks, predonisolone is decreased to 0.6mg/kg/day, and ciclosporin (2mg/kg/day) is started once a day. Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.)
Steroid + ciclosporin group: Immunosupressive therapy is started by predonisolone 0.6mg/kg/day and ciclosporin 2mg/kg/day (once a day). Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) The dose of predonisolone is decreased by 5mg/day in 2 to 4 weeks after remission. Ciclosporin is continued after remission. (The target C2 is 600-800 ng/mL.) The cases who do not reach remission after 4 weeks, predonisolone is decreased by 5mg/4-8week, and ciclosporin is continued for 6 months. The target C2 is 800-1000ng/mL. At 6 months after, the therapy of non-respnder is not restricted.
Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of MedicineNULL16years-oldNot applicableMale and Female50Phase 4Japan